Telmisartan inhibits CD4-positive lymphocyte migration independent of the angiotensin type 1 receptor via peroxisome proliferator-activated receptor-γ

Hypertension

Volumn 51, Issue 2, 2008, Pages 259-266

  Walcher, Daniel ^a   Hess, Katharina ^a   Heinz, Philipp ^a   Petscher, Kerstin ^a   Vasic, Dusica ^a   Kintscher, Ulrich ^b   Clemenz, Markus ^b   Hartge, Martin ^b   Raps, Katrin ^a   Hombach, Vinzenz ^a   Marx, Nikolaus ^a  

^a UNIVERSITY OF ULM   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Angiotensin type 1 receptor blocker; CD4 positive lymphocytes; Migration; PPAR ; Telmisartan

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; F ACTIN; N (2 BENZOYLPHENYL) O [2 (METHYL 2 PYRIDINYLAMINO)ETHYL]TYROSINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHATIDYLINOSITOL 3 KINASE; PIOGLITAZONE; RNA; ROSIGLITAZONE; TELMISARTAN;

ARTICLE; CD4+ T LYMPHOCYTE; CELL MIGRATION; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN FUNCTION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ACTINS; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIGENS, CD; BENZIMIDAZOLES; BENZOATES; BIOLOGICAL TRANSPORT; CD4-POSITIVE T-LYMPHOCYTES; CELL ADHESION MOLECULES; CELL MOVEMENT; CELLS, CULTURED; CHEMOKINE CXCL12; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; PPAR GAMMA; RECEPTOR, ANGIOTENSIN, TYPE 1;

EID: 38549161568     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.107.099028     Document Type: Article

References (29)

1. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352:1685-1695.
2. Heller EA, Liu E, Tager AM, Yuan Q, Lin AY, Ahluwalia N, Jones K, Koehn SL, Lok VM, Aikawa E, Moore KJ, Luster AD, Gerszten RE. Chemokine CXCL10 promotes atherogenesis by modulating the local balance of effector and regulatory T cells. Circulation. 2006;113:2301-2312.
3. Veillard NR, Steffens S, Pelli G, Lu B, Kwak BR, Gerard C, Charo IF, Mach F. Differential influence of chemokine receptors CCR2 and CXCR3 in development of atherosclerosis in vivo. Circulation. 2005;112:870-878.
4. Goebel M, Clemenz M, Unger T. Effective treatment of hypertension by AT(1) receptor antagonism: the past and future of telmisartan. Expert Rev Cardiovasc Ther. 2006;4:615-629.
5. Sugimoto K, Qi NR, Kazdova L, Pravenec M, Ogihara T, Kurtz TW. Telmisartan but not valsartan increases caloric expenditure and protects against weight gain and hepatic steatosis. Hypertension. 2006;47:1003-1009.
6. Benson SC, Pershadsingh HA, Ho CI, Chittiboyina A, Desai P, Pravenec M, Qi N, Wang J, Avery MA, Kurtz TW. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension. 2004;43:993-1002.
7. Clasen R, Schupp M, Foryst-Ludwig A, Sprang C, Clemenz M, Krikov M, Thone-Reineke C, Unger T, Kintscher U. PPARgamma-activating angiotensin type-1 receptor blockers induce adiponectin. Hypertension. 2005;46:137-143.
8. Schupp M, Janke J, Clasen R, Unger T, Kintscher U. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation. 2004;109:2054-2057.
9. Schupp M, Clemenz M, Gineste R, Witt H, Janke J, Helleboid S, Hennuyer N, Ruiz P, Unger T, Staels B, Kintscher U. Molecular characterization of new selective peroxisome proliferator-activated receptor gamma modulators with angiotensin receptor blocking activity. Diabetes. 2005;54:3442-3452.
10. Tuck ML. Angiotensin-receptor blocking agents and the peroxisome proliferator-activated receptor-gamma system. Curr Hypertens Rep. 2005;7:240-243.
11. Kurtz TW, Pravenec M. Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists: beyond the renin-angiotensin system. J Hypertens. 2004;22:2253-2261.
12. Kurtz TW. Treating the metabolic syndrome: telmisartan as a peroxisome proliferator-activated receptor-gamma activator. Acta Diabetol. 2005;42(suppl 1):S9-S16.
13. Kintscher U, Unger T. Vascular protection in diabetes: a pharmacological view of angiotensin II type 1 receptor blockers. Acta Diabetol. 2005;42(suppl 1):S26 -S32.
14. Staels B, Fruchart JC. Therapeutic roles of peroxisome proliferator-activated receptor agonists. Diabetes. 2005;54:2460-2470.
15. Clark RB, Bishop Bailey D, Estrada Hernandez T, Hla T, Puddington L, Padula SJ. The nuclear receptor PPAR gamma and immunoregulation: PPAR gamma mediates inhibition of helper T cell responses. J Immunol. 2000;164:1364-1371.
16. Marx N, Kehrle B, Kohlhammer K, Grub M, Koenig W, Hombach V, Libby P, Plutzky J. PPAR activators as antiinflammatory mediators in human T lymphocytes: implications for atherosclerosis and transplantation-associated arteriosclerosis. Circ Res. 2002;90:703-710.
17. Walcher D, Aleksic M, Jerg V, Hombach V, Zieske A, Homma S, Strong J, Marx N. C-peptide induces chemotaxis of human CD4-positive cells - involvement of pertussis toxin-sensitive G-proteins and PI 3-kinase. Diabetes. 2004;53:1664-1670.
18. Al-Aoukaty A, Rolstad B, Maghazachi AA. Recruitment of pleckstrin and phosphoinositide 3-kinase gamma into the cell membranes, and their association with G beta gamma after activation of NK cells with chemokines. J Immunol. 1999;162:3249-3255.
19. Arber S, Barbayannis FA, Hanser H, Schneider C, Stanyon CA, Bernard O, Caroni P. Regulation of actin dynamics through phosphorylation of cofilin by LIM-kinase. Nature. 1998;393:805-809.
20. Serrador JM, Nieto M, Sanchez-Madrid F. Cytoskeletal rearrangement during migration and activation of T lymphocytes. Trends Cell Biol. 1999;9:228-233.
21. Sanchez-Madrid F, del Pozo MA. Leukocyte polarization in cell migration and immune interactions. Embo J. 1999;18:501-511.
22. Caballero R, Delpon E, Valenzuela C, Longobardo M, Gonzalez T, Tamargo J. Direct effects of candesartan and eprosartan on human cloned potassium channels involved in cardiac repolarization. Mol Pharmacol. 2001;59:825-836.
23. Marx N, Duez H, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells. Circ Res. 2004;94:1168-1178.
24. Kintscher U, Goetze S, Wakino S, Kim S, Nagpal S, Chandraratna RA, Graf K, Fleck E, Hsueh WA, Law RE. Peroxisome proliferator-activated receptor and retinoid X receptor ligands inhibit monocyte chemotactic protein-1-directed migration of monocytes. Eur J Pharmacol. 2000;401:259-270.
25. Stangier J, Su CA, Hendriks MG, van Lier JJ, Sollie FA, Oosterhuis B, Jonkman JH. The effect of telmisartan on the steady-state pharmacokinetics of digoxin in healthy male volunteers. J Clin Pharmacol. 2000;40:1373-1379.
26. Stangier J, Su CA, van Heiningen PN, Meinicke T, van Lier JJ, de Bruin H, Tamminga WJ, Jonkman JH. Inhibitory effect of telmisartan on the blood pressure response to angiotensin II challenge. J Cardiovasc Pharmacol. 2001;38:672-685.
27. Goetze S, Eilers F, Bungenstock A, Kintscher U, Stawowy P, Blaschke F, Graf K, Law RE, Fleck E, Grafe M. PPAR activators inhibit endothelial cell migration by targeting Akt. Biochem Biophys Res Commun. 2002;293:1431-1437.
28. Folli F, Kahn CR, Hansen H, Bouchie JL, Feener EP. Angiotensin II inhibits insulin signaling in aortic smooth muscle cells at multiple levels. A potential role for serine phosphorylation in insulin/angiotensin II crosstalk. J Clin Invest. 1997;100:2158-2169.
29. Ait-Oufella H, Salomon BL, Potteaux S, Robertson AKL, Gourdy P, Zoll J, Merval R, Esposito B, Cohen JL, Fisson S, Flavell RA, Hansson GK, Klatzmann D, Tedgui A, Mallat Z. Natural regulatory T cells control the development of atherosclerosis in mice. Nature Medicine. 2006;12:178-180.